ライフサイエンスコーパス: spasticity

1 d provide insight into mechanisms underlying spasticity.

2 ally characterised by progressive lower limb spasticity.

3 pathic pain, but also epilepsy, tremors, and spasticity.

4 jerks, inability to initiate movements, and spasticity.

5 rticospinal tract and progressive lower limb spasticity.

6 Hypotonia gives way in adult life to spasticity.

7 ew perspective in the clinical evaluation of spasticity.

8 sample of people with multiple sclerosis and spasticity.

9 ts with stable multiple sclerosis and muscle spasticity.

10 by progressive lower-extremity weakness and spasticity.

11 e clear ability of botulinum toxin to reduce spasticity.

12 onically active in the control of tremor and spasticity.

13 dren with perinatal brain damage who develop spasticity.

14 for a role of brainstem serotonin neurons in spasticity.

15 ma, stimulation of appetite, and spinal cord spasticity.

16 ncement of stretch reflexes is suggestive of spasticity.

17 sly progressive lower extremity weakness and spasticity.

18 amyloidosis, producing dementia, ataxia, and spasticity.

19 lly-feasible time-point after injury reduced spasticity.

20 tor processing in the spinal cord leading to spasticity.

21 l symptoms, including movement disorders and spasticity.

22 d axial hypotonia with variable appendicular spasticity.

23 seizures, irritability, ataxia, and extreme spasticity.

24 tnatal microcephaly and epilepsy and develop spasticity.

25 ed by intellectual disability, seizures, and spasticity.

26 ceptor 2C (5-HT2CR) contributing to post-SCI spasticity.

27 inoids for the treatment of chronic pain and spasticity.

28 ongenital cataracts, growth retardation, and spasticity.

29 but urinary symptoms were rare, despite the spasticity.

30 s of the nervous system such as seizures and spasticity.

31 flexes and/or diffuse tendon reflexes and/or spasticity.

32 nsitization and chronic pain associated with spasticity.

33 y result in a reduction of hyperreflexia and spasticity.

34 s are a novel class of therapeutic agent for spasticity.

35 mplicated in epilepsy, neuropathic pain, and spasticity.

36 h increased tone and some of which have limb spasticity.

37 in subjects with motor disorders affected by spasticity.

38 the published data cohort for myoclonus and spasticity (19.4%, 16.6-22.2 and 15.0%, 12.5-17.6, respe

39 onia (91%) was seen, followed by progressive spasticity (82%, median onset = 15 months) and dystonia

40 -OBS cohort was low, including myoclonus and spasticity (9.3%, 95% CI 3.8-15.0), and seizures (2.8%,

41 However, both lines developed spasticity (a "clasping" phenotype) at a median age of 2

42 Spasticity, a common complication after spinal cord inju

43 on in the upper limb muscles on muscle tone, spasticity, active movement, and function.

44 h restores endogenous inhibition and reduces spasticity after SCI in rats.

45 5-HT2B/C is required for the development of spasticity after spinal cord injury and during amyotroph

46 No spasticity, albinism, or hematological symptoms were rep

47 major syndromic categories: (1) ataxia, (2) spasticity and (3) global neurodevelopmental impairment.

48 n includes early-onset nystagmus, ataxia and spasticity and a wide range of severity.

49 me characterized by intellectual disability, spasticity and absent speech.

50 t with movement deficits including weakness, spasticity and an inability to isolate movement to one o

51 displayed a neurodegenerative phenotype with spasticity and ataxia by 15 mo.

52 Progressive limb spasticity and cerebellar ataxia are frequently found to

53 Prominent features include pyramidal spasticity and cerebellar ataxia, but the underlying pat

54 by nystagmus, psychomotor delay, progressive spasticity and cerebellar signs.

55 of several neurological disorders, including spasticity and chronic pain following spinal cord injury

56 with early onset, characterized by seizures, spasticity and developmental delays, ultimately leading

57 inal tracts and dorsal columns, resulting in spasticity and difficulty walking.

58 ommon early comorbidities included seizures, spasticity and disordered sleep.

59 Supportive treatment focused on spasticity and drooling, and was effective in the indivi

60 ith signs of white matter dysfunction (i.e., spasticity and hyperreflexia).

61 isorder characterized by mental retardation, spasticity and ichthyosis.

62 ulates activity in spinal pathways to reduce spasticity and improve functional recovery are poorly un

63 ts with upper motor neurone syndrome, reduce spasticity and improve voluntary movement and active fun

64 t syndrome, X-linked myoclonic epilepsy with spasticity and intellectual disability, Partington syndr

65 sorder manifested by lower limb weakness and spasticity and length-dependent axonopathy of corticospi

66 We found a correlation between signs of spasticity and long-interval intracortical inhibition in

67 e devastating neurological disorders such as spasticity and mental retardation.

68 ological techniques was used to characterize spasticity and motor phenotype.

69 caudal to hemisection had significantly less spasticity and muscle wasting and greater mobility at th

70 therapy that treats the underlying causes of spasticity and not only its symptoms.

71 Clinical features included severe spasticity and nystagmus.

72 hat cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclero

73 ce of a treatment effect on patient-reported spasticity and pain (p=0.003), with improvement in spast

74 ic areas such as the role of cannabinoids in spasticity and pain and new treatments for cognitive imp

75 ated in disorders such as multiple sclerosis spasticity and pain, basic research is discovering inter

76 Spasticity and paralysis were observed in chronically in

77 n mice, manifested clinically by progressive spasticity and paralysis.

78 ns causes neuropathy that leads to hind limb spasticity and premature death.

79 e mental impairment, growth retardation, and spasticity and punctuated by sometimes fatal episodes of

80 l AMPA receptors and their role in mediating spasticity and rigidity.

81 ensation also contributed significantly, but spasticity and strength were not significant in the mode

82 oids are useful for symptomatic treatment of spasticity and tremor in chronic-relapsing experimental

83 myelin antigens Biozzi ABH mice also develop spasticity and tremor.

84 is a genetic disorder that causes lower limb spasticity and weakness and intellectual disability.

85 characterized principally by lower extremity spasticity and weakness due to a length-dependent, retro

86 are characterised clinically by progressive spasticity and weakness of the lower limbs, and patholog

87 t not exclusively, by progressive lower limb spasticity and weakness resulting from distal degenerati

88 e disorders characterized by lower-extremity spasticity and weakness, are most commonly caused by mut

89 s syndromes characterized by lower extremity spasticity and weakness, with distal axonal degeneration

90 l disorders characterized by lower extremity spasticity and weakness.

91 ders characterized by progressive lower-limb spasticity and weakness.

92 orticospinal tracts, resulting in lower limb spasticity and weakness.

93 ypically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.

94 rigin characterized by progressive dementia, spasticity, and cerebellar ataxia, with onset at around

95 vere disability, microcephaly, hearing loss, spasticity, and characteristic brain imaging findings.

96 icial tool for the treatment of cancer pain, spasticity, and chronic nonmalignant pain.

97 tor coordination and develop slurred speech, spasticity, and cognitive impairments.

98 disease characterized by mental retardation, spasticity, and congenital ichthyosis.

99 acterized by ichthyosis, mental retardation, spasticity, and deficient activity of fatty aldehyde deh

100 IFN-gamma(-/-) mice characterized by ataxia, spasticity, and dystonia, hallmarks of brain-specific di

101 ve cognitive decline associated with ataxia, spasticity, and eventually seizures.

102 eral extensor plantar reflexes, occasionally spasticity, and frequently psychiatric symptoms.

103 enesis, mental retardation, adducted thumbs, spasticity, and hydrocephalus.

104 Seizures, spasticity, and intellectual disability can be present,

105 the immune response, appetite, reproduction, spasticity, and pain.

106 s ADNFLE), a syndrome of mental retardation, spasticity, and tapetoretinal degeneration (MRST); and a

107 ogliosis, loss of descending inhibition, and spasticity are responsible for approximately 40% of case

108 n of antagonist muscles is characteristic of spasticity arising from perinatal brain damage but not i

109 ceps brachii) motor neurons in subjects with spasticity arising from perinatal brain damage.

110 manifestation of traditional post-traumatic spasticity as a basis for this activity.

111 ne dystonia with or without parkinsonism and spasticity as part of a mixed neurodegenerative disorder

112 d balance in the rotarod test, and increased spasticity as shown by a clasping phenotype.

113 s seen in those with unilateral or bilateral spasticity, as in those with a dyskinetic or ataxic disa

114 IDD for cancer pain, nonmalignant pain, and spasticity, as well as a new study of cerebrospinal flui

115 rious disease models and alleviates pain and spasticity associated with multiple sclerosis in humans.

116 developmental delay, acquired microcephaly, spasticity, ataxia, and hypoglycorrhachia.

117 ed of extrapyramidal movement abnormalities, spasticity, ataxia, cognitive deficit and sometimes epil

118 s, unilateral DLF lesions provide a model of spasticity but produce only several components of a more

119 Since 1980, modification of spasticity by means of orally administered drugs, intram

120 definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new ho

121 Spasticity can, therefore, be measured through electroph

122 l nervous system resulting primarily in limb spasticity, cognitive impairment, nystagmus, and spastic

123 Spasticity comorbidity was present in 79/230 (34.3%) chi

124 Diffuse spasticity, dementia, vegetative state, or death ensues.

125 trophy gene at 12p13; 4) the choreoathetosis/spasticity disease locus on 1p that lies in a region con

126 uana for chronic pain, neuropathic pain, and spasticity due to multiple sclerosis is supported by hig

127 ts to test the hypothesis that inhibition of spasticity, due to CNS autoimmunity, could be controlled

128 functional involvement by weakness, wasting, spasticity, dysarthria or dysphagia of one central nervo

129 childhood, followed by progressive dystonia, spasticity, dysphagia, mental deterioration, paranoia an

130 Spasticity, dystonia, tremor and migraine were variably

131 The short-term benefits of baclofen on spasticity (e.g. management of muscle spasms that may ot

132 nset bilateral optic atrophy and later-onset spasticity, extrapyramidal dysfunction, and cognitive de

133 t onset Parkinson's disease or earlier onset spasticity followed by parkinsonism.

134 Subjects with spasticity, from brain damage acquired in adulthood were

135 or(B) agonist, is used to reduce symptoms of spasticity (hyperreflexia, increases in muscle tone, inv

136 re used to develop a conceptual framework of spasticity impact, and to generate a pool of items with

137 s a re-analysis of the basic assumption that spasticity impairs voluntary movement and a review of th

138 3 quantitatively ameliorated both tremor and spasticity in diseased mice.

139 activity of 5-HT2B/C receptors and abolished spasticity in end-stage mice.

140 with upper motor neuron defects that lead to spasticity in humans.

141 rrently in clinical use for the treatment of spasticity in multiple sclerosis (MS) patients and to al

142 sed, interval-level measure of the impact of spasticity in multiple sclerosis.

143 lated to chemotherapy, neuropathic pain, and spasticity in multiple sclerosis.

144 serotonergic system could be useful to treat spasticity in neurological diseases.

145 diazepines are commonly used to treat muscle spasticity in spinal cord injured subjects and the gamma

146 e and its high sensitivity in examination of spasticity in stroke.

147 mode of exclusion; induction and control of spasticity in the ABH mouse model of multiple sclerosis;

148 rojections simply become unmasked as part of spasticity, independent of the age of occurrence of the

149 Spasticity is a complicating sign in multiple sclerosis

150 Spasticity is a disabling complication of stroke, and it

151 Spasticity is a painful symptom and can severely restric

152 Spasticity is associated with the DH hyperexcitability r

153 Spasticity is most commonly defined as an inappropriate,

154 Secondary to the UMNl esion,which causes spasticity, is a pathological response by muscle - namel

155 aracterized by weakness, muscle atrophy, and spasticity, is the most common adult-onset motor neuron

156 294/315 assessable children, 15/294 had pure spasticity, leaving 279/294 with dystonia classified as

157 Consistent with spasticity mitigating motor symptoms, selective deletion

158 selective death of motor neurons leading to spasticity, muscle atrophy and paralysis.

159 selective death of motor neurons leading to spasticity, muscle wasting and paralysis.

160 niques incorporate the patient experience of spasticity, nor how it affects people's daily lives.

161 ising from perinatal brain damage but not in spasticity occurring after brain damage in adulthood.

162 Spasticity occurs in a wide range of neurological diseas

163 disability, childhood hypotonia, progressive spasticity of lower limbs, and abnormal craniofacial fea

164 Thirty-eight subjects, aged 8-30 years, with spasticity of perinatal origin (11 hemiplegic, 11 quadri

165 rn was observed in older subject groups with spasticity of perinatal origin.

166 Physical activity, including the chronic spasticity of SQCP, was estimated from the ratio of TEE

167 Spasticity of the biceps brachii muscle was assessed usi

168 In post-stroke patients with spasticity of the biceps brachii, we found involuntary m

169 stic paraplegias (HSPs) are characterized by spasticity of the leg muscles due to axonal degeneration

170 ive' neurological syndromes characterized by spasticity of the legs.

171 that are characterized by abnormal gait and spasticity of the lower limbs.

172 d primarily by hyperreflexia and progressive spasticity of the lower limbs.

173 corticospinal motor neurons and progressive spasticity of the lower limbs.

174 cular injections of botulinum toxin A reduce spasticity of the wrist and finger muscles and associate

175 xin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke.

176 penditure, such as for physical activity and spasticity, of children with SQCP was low.

177 o quantify the perspectives of the impact of spasticity on people with multiple sclerosis.

178 mia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clin

179 c pain states, including disorders involving spasticity or myofascial pain, neuropathic pain, and chr

180 d as either pure with predominant lower limb spasticity, or complex where spastic paraplegia is compl

181 l delay but without macrocephaly, hypotonia, spasticity, or seizures.

182 nifying feature of prominent lower extremity spasticity, owing to a length-dependent axonopathy of co

183 y of WM damage correlated with the degree of spasticity (P < .05, family-wise error corrected) and co

184 strostomy, communication problems, mobility, spasticity, pain, cognition, depression and emotional la

185 tness, ataxia, fatigue, bladder dysfunction, spasticity, pain, cognitive deficits, depression, and ps

186 eported outcome measures assessed aspects of spasticity, physical and psychological impact, and walki

187 corticospinal tract degeneration, and motor spasticity recapitulating key aspects of FTLD and primar

188 ent consists of orthotics, physical therapy, spasticity reduction treatment and surgical correction.

189 BAB receptor agonist commonly used to relief spasticity related to motor disorders.

190 city and pain (p=0.003), with improvement in spasticity reported in 61% (n=121, 95% CI 54.6-68.2), 60

191 can represent a novel therapy in modulating spasticity/rigidity of spinal origin and that astrocytes

192 Spasticity/rigidity were identified by simultaneous meas

193 The 88-item Multiple Sclerosis Spasticity Scale (MSSS-88) is a reliable and valid, pati

194 ials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7

195 rimary outcome measure was change in overall spasticity scores, using the Ashworth scale.

196 l delay, intellectual disability, hypotonia, spasticity, seizures, sensorineural hearing loss, cortic

197 nistered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re-u

198 rols and mice with spinal cord injuries with spasticity, spinal-to-sciatic DCS reduced transit and st

199 ty involvement and recent methods to control spasticity, such as selective dorsal rhizotomy and admin

200 ction model, ephrinB3(-/-) mice show greater spasticity than wild-type mice for 2 mo, with slightly g

201 o investigate the severe muscle weakness and spasticity that precede the death of these animals near

202 associated with the neuropathy, for example, spasticity, the type of neuropathy and the other neurolo

203 tients had microcephaly, short stature, mild spasticity, thoracic scoliosis, hyperextendable MCP join

204 of serotonin neurons is necessary to trigger spasticity through the 5-HT2B/C receptor.

205 chidonoyl glycerol-significantly ameliorated spasticity to an extent comparable with that observed pr

206 greatly to include numerous focal dystonias, spasticity, tremors, cosmetic applications, migraine and

207 378 and SAD448) were identified that control spasticity via action on the peripheral nerve CB1 recept

208 Spasticity was quantified by muscle displacements and co

209 natal (dpn) and are characterized by ataxia, spasticity, weight loss and hypercholesterolemia.

210 abinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale.

211 from Conus textile, causes hyperactivity and spasticity when injected intracerebral ventricularly int

212 s with neurological diseases associated with spasticity, who had IDDS system implanted and were unabl

213 n most cases, characterized by a progressive spasticity with neuropathy, cognitive impairment and a t

214 ia, nystagmus, dorsal column dysfuction, and spasticity with upper motor neuron dysfunction.

215 worsened after partial cervical lesions and spasticity worsened after complete transection.

216 X-linked parkinsonism with spasticity (XPDS) presents either as typical adult onset